Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
05.09. - 12:45 Uhr
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET. » Mehr auf accesswire.com
14.06. - 13:05 Uhr
CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Live webcast fireside chat on Wednesday, June 21st at 2:30 PM ET HOUSTON, TX / ACCESSWIRE / June 14, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 2:30 PM ET. The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space. » Mehr auf accesswire.com
27.04. - 12:45 Uhr
CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study
Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET. As part of the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President, Clinical Operations of CNS Pharmaceuticals will discuss the progress of its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. » Mehr auf accesswire.com
Unternehmenszahlen
| (EUR) | Sep. 2023 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | 4,27 Mio | 22,48% |
| EBITDA | 4,27 Mio | 22,54% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 9,85 Mio € |
Anzahl Aktien | 5,25 Mio |
52 Wochen-Hoch/Tief | 4,01 € - 0,56 € |
| Dividenden | Nein |
Beta | 1,13 |
KGV (PE Ratio) | 0,45 |
KGWV (PEG Ratio) | 0,0152 |
KBV (PB Ratio) | 4,94 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
CNS Pharmaceuticals, Inc. ist ein klinisches Pharmaunternehmen, das sich mit der Entwicklung von Krebsmedikamenten zur Behandlung von Tumoren des Gehirns und des zentralen Nervensystems befasst. Der führende Arzneimittelkandidat des Unternehmens ist Berubicin, ein Anthrazyklin, das sich in klinischen Studien der Phasen I und II befindet und zur Behandlung von Glioblastoma multiforme eingesetzt wird. Das Unternehmen hat Lizenzvereinbarungen mit Houston Pharmaceuticals, Inc. und dem University of Texas M.D. Anderson Cancer Center sowie mit Animal Life Sciences, LLC; und eine Entwicklungsvereinbarung mit WPD Pharmaceuticals Inc. sowie eine Kooperationsvereinbarung mit Reata Pharmaceuticals, Inc. Das Unternehmen wurde im Jahr 2017 gegründet und hat seinen Sitz in Houston, Texas.
| Name | CNS PHARMAC. INC. DL-,001 Aktie |
| CEO | John Michael Climaco Esq., J.D. |
| Sitz | Houston,
tx USA |
| Website | |
| Industrie | Chemikalien |
| Börsengang | 08.11.2019 |
| Mitarbeiter | 3 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | CNSP |
Assets entdecken
Shareholder von CNS PHARMAC. INC. DL-,001 Aktie investieren auch in folgende Assets
